Tag Archives: Eagle Pharmaceuticals

A Director at Eagle Pharmaceuticals is Exercising Options

Yesterday it was reported that a Director at Eagle Pharmaceuticals (EGRX – Research Report), Steven Ratoff, exercised options to buy 2,340 EGRX shares at $8.78 a share, for a total transaction value of $20.55K. The options were close to expired

Eagle Pharmaceuticals (EGRX) Gets a Buy Rating from RBC Capital

RBC Capital analyst Randall Stanicky maintained a Buy rating on Eagle Pharmaceuticals (EGRX – Research Report) today and set a price target of $59.00. The company’s shares closed last Monday at $40.94. According to TipRanks.com, Stanicky is currently ranked with

Mizuho Securities Reiterates a Sell Rating on Eagle Pharmaceuticals

Mizuho Securities analyst Irina Rivkind Koffler reiterated a Sell rating on Eagle Pharmaceuticals (NASDAQ: EGRX) today and set a price target of $40. The company’s shares opened today at $59. Rivkind Koffler said: “We don’t yet have this product in

Mizuho Securities Keeps a Sell Rating on Eagle Pharmaceuticals

In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Sell rating on Eagle Pharmaceuticals (NASDAQ: EGRX), with a price target of $40. The company’s shares closed yesterday at $52.38, close to its 52-week low of $45.05.

Analysts Conflicted on These Healthcare Names: Eagle Pharmaceuticals (NASDAQ: EGRX) and Ascendis Pharma (NASDAQ: ASND)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eagle Pharmaceuticals (NASDAQ: EGRX) and Ascendis Pharma (NASDAQ: ASND). Eagle Pharmaceuticals (NASDAQ: EGRX) Mizuho Securities analyst Irina Rivkind Koffler reiterated a Sell rating on Eagle

Piper Jaffray Reaffirms Their Buy Rating on Eagle Pharmaceuticals

In a report released yesterday, David Amsellem from Piper Jaffray reiterated a Buy rating on Eagle Pharmaceuticals (NASDAQ: EGRX), with a price target of $79. The company’s shares closed yesterday at $59.02. According to TipRanks.com, Amsellem is ranked 0 out